Tanezumab is under regulatory review for chronic pain due to moderate-to-severe osteoarthritis (OA), a debilitating condition that impacts millions around the world

Pfizer is driven by a desire to improve the lives of millions of patients suffering from OA, a leading cause of chronic pain and disability worldwide.^1,2 OA can have life-altering physical, social, psychological and economic impacts for patients, their loved ones and society.^3,4,5 Currently available treatment options for moderate-to-severe OA do not meet all patients’ needs, and many cycle through multiple therapies to find relief from their pain. Pfizer is committed to raising awareness and understanding of the burden of chronic OA pain and the significant unmet needs for patients, and to driving innovation in the treatment of this debilitating condition.

​​​​Together with Eli Lilly and Company, Pfizer is leveraging our deep clinical expertise to progress tanezumab, a potential first-in-class treatment for chronic OA pain. Tanezumab is a monoclonal antibody that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor inhibitors. Regulatory applications for tanezumab 2.5 mg administered subcutaneously have been accepted for review in the U.S., EU and Japan for the treatment of adult patients with chronic pain due to moderate-to-severe OA for whom the use of other analgesics is ineffective or inappropriate, with regulatory decisions expected in 2021. The applications were the largest Pfizer has ever dispatched, and their breadth reflects our commitment and the extensive clinical evidence gathered for tanezumab.